Evidence map›Paper›PMID 32277831›Full record

SynthesisAdvances in nutrition (Bethesda, Md.)2020

Fermented Dairy Products, Probiotic Supplementation, and Cardiometabolic Diseases: A Systematic Review and Meta-analysis.

Judit Companys, Laura Pla-Pagà, Lorena Calderón-Pérez, Elisabet Llauradó, Rosa Solà, Anna Pedret, Rosa M Valls

Open access · bronzeAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Advances in nutrition (Bethesda, Md.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 10 pooled it
14.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 10 syntheses or guidelines pooled it, 147 citations in OpenAlex.

  1. The doseFrontiers in nutrition · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Observational

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Judit CompanysEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Laura Pla-PagàEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Lorena Calderón-PérezEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Elisabet LlauradóEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Rosa SolàEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Anna PedretEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Rosa M VallsEurecat, Centre Tecnològic de Catalunya, Unitat de Nutrició i Salut, Reus, Spain.
Departament de Salut · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fermented dairy foods (FDFs) and probiotics are promising tools for the prevention and management of cardiometabolic diseases (CMDs), respectively. The relation between the regular consumption of FDFs and CMD risk factors was assessed by prospective cohort studies (PCSs), and the effect of probiotic supplementation added into a dairy matrix on CMD parameters was evaluated by randomized controlled trials (RCTs). Moreover, the effects of probiotic supplementation added into a dairy matrix were compared with those administered in capsule/powder form. Twenty PCSs and 52 RCTs met the inclusion criteria for the systematic review and meta-analysis. In PCSs, fermented milk was associated with a 4% reduction in risk of stroke, ischemic heart disease, and cardiovascular mortality [RR (95% CI); 0.96 (0.94, 0.98)]; yogurt intake was associated with a risk reduction of 27% [RR (95% CI); 0.73 (0.70, 0.76)] for type 2 diabetes (T2D) and 20% [RR (95% CI); 0.80 (0.74, 0.87)] for metabolic syndrome development. In RCTs, probiotic supplementation added into dairy matrices produced a greater reduction in lipid biomarkers than when added into capsules/powder in hypercholesterolemic subjects, and probiotic supplementation by capsules/powder produced a greater reduction in T2D biomarkers than when added into dairy matrices in diabetic subjects. Both treatments (dairy matrix and capsules/powder) resulted in a significant reduction in anthropometric parameters in obese subjects. In summary, fermented milk consumption is associated with reduced cardiovascular risk, while yogurt intake is associated with a reduced risk of T2D and metabolic syndrome development in the general population. Furthermore, probiotic supplementation added into dairy matrices could be considered beneficial for lowering lipid concentrations and reducing anthropometric parameters. Additionally, probiotic capsule/powder supplementation could contribute to T2D management and reduce anthropometric parameters. However, these results should be interpreted with caution due to the heterogeneity of the studies and the different probiotic strains used in the studies. This trial is registered with PROSPERO (CRD42018091791) and the protocol can be accessed at http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42018091791.

Indexed as

Cultured Milk ProductsMetabolic SyndromeProbioticsAnimalsDairy ProductsDietHumansMilkcardiometabolic diseasefermented dairyhypercholesterolemiaobesityprobioticstype 2 diabetes

Identifiers

PMID32277831
PMCPMC7360468
OpenAlexW3015331944

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.